Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GYROSCOPE THERAPEUTICS HOLDINGS PLC

(VISN)
SummaryQuotesNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medical Research Institute to Develop Novel Gene Therapy Capsids

06/22/2021 | 01:00am EDT

Gyroscope Therapeutics Holdings plc announced the company has entered a research collaboration with Children’s Medical Research Institute (“CMRI”) in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies. A team of researchers from CMRI and Gyroscope will work together in the design and screening of capsid libraries to identify novel capsids for enhanced delivery of ocular gene therapies. Under the agreement, Gyroscope has an option to obtain an exclusive licence for ocular uses of capsids developed through the partnership. The CMRI team is led by Associate Professor Leszek Lisowski, Ph.D., MBA, a recognised expert in viral vector-based gene therapy, vectorology and genotoxicity, with more than 15 years of experience in capsid generation and discovery.


© S&P Capital IQ 2021
All news about GYROSCOPE THERAPEUTICS HOLDINGS PLC
09/30Gyroscope Therapeutics Holdings plc Announces Presentation of Positive Interim Phase I/..
CI
06/22Gyroscope Therapeutics Announces Research Collaboration Agreement with Children’s Medic..
CI
05/07Gyroscope Therapeutics Holdings plc has withdrawn its IPO in the amount of $148.5 milli..
CI
04/16Gyroscope Therapeutics Holdings plc has filed an IPO in the amount of $100 million.
CI
01/11Gyroscope Therapeutics Holdings Limited Auditor Raises 'Going Concern' Doubt
CI
2019Gyroscope Therapeutics Limited acquired Orbit Biomedical Inc. from Syncona Portfolio Lt..
CI
More news
Financials (USD)
Sales 2020 2,97 M - -
Net income 2020 -33,5 M - -
Net cash 2020 12,6 M - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 614 M 614 M -
EV / Sales 2019
EV / Sales 2020 -
Nbr of Employees 167
Free-Float 49,5%
Chart GYROSCOPE THERAPEUTICS HOLDINGS PLC
Duration : Period :
Gyroscope Therapeutics Holdings plc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Khurem Farooq Chief Executive Officer & Director
Jessica Stitt Chief Financial Officer
Christopher John Hollowood Chairman
Jane Hughes Chief Scientific Officer
Ian Pitfield Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
GYROSCOPE THERAPEUTICS HOLDINGS PLC0.00%614
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414